Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

• Main Authors: Innocent Valéa (Author), Samuel Adjei (Author), Effua Usuf (Author), Ousmane Traore (Author), Daniel Ansong (Author), Halidou Tinto (Author), Harry Owusu Boateng (Author), Athanase Mwinessobaonfou Some (Author), Patrick Buabeng (Author), Johan Vekemans (Author), Amos Kotey (Author), Pascale Vandoolaeghe (Author), Mark Cullinane (Author), Magali Traskine (Author), Florence Ouedraogo (Author), David Sambian (Author), Marc Lievens (Author), Marc Christian Tahita (Author), Erik Jongert (Author), Palpouguini Lompo (Author), Ali Idriss (Author), Dorota Borys (Author), Sayouba Ouedraogo (Author), Frank Prempeh (Author), Lode Schuerman (Author), Hermann Sorgho (Author), Tsiri Agbenyega (Author)
• Format: Book
• Published: Taylor & Francis Group, 2020-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

RTS,S/AS01E malaria vaccine contains the hepatitis B virus surface antigen and may thus serve as a potential hepatitis B vaccine. To evaluate the impact of RTS,S/AS01E when implemented in the Expanded Program of Immunization, infants 8-12 weeks old were randomized to receive either RTS,S/AS01E or a...